Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells

Use of the antibody trastuzumab to kill HER2+ breast cancer cells is an attractive therapy because of its specificity and minimal adverse effects. However, a large fraction of HER2+ positive patients are or will become resistant to this treatment. No other markers are used to determine sensitivity t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kute, Timothy, Stehle, Jr., John R., Ornelles, David, Walker, Natalie, Delbono, Osvaldo, Vaughn, James P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489736/
https://www.ncbi.nlm.nih.gov/pubmed/23162748
http://dx.doi.org/10.4161/onci.20447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489736/
https://www.ncbi.nlm.nih.gov/pubmed/23162748
http://dx.doi.org/10.4161/onci.20447

Ejemplares similares